Infographic: Which Companies are Developing Ranibizumab Biosimilars?

Lucentis (ranibizumab) faces oncoming competition from 4 companies that are developing proposed biosimilars.

Related Content:

Ophthalmology

International Biosimilars Trade Group Appoints New Leadership for 2022

Developers Advised to Challenge Regulatory Standards to Speed Development of Biosimilars

Review: Biobetters and Biosimilars Set to Emerge in Ophthalmology